Early trial halted after testing new cancer drug combo
NCT ID NCT02819752
Summary
This early-stage study aimed to find a safe dose for combining a new immunotherapy drug (pembrolizumab) with standard chemotherapy and radiation for patients with advanced head and neck cancer. It focused on measuring side effects, especially skin and mouth reactions, in a small group of patients. The trial was terminated early, enrolling only 3 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Royal Marsden Hospital NHS Foundation Trust
London, SW3 6JJ, United Kingdom
Conditions
Explore the condition pages connected to this study.